Search

everythinglearnresearchcommunity

for

Search:↓

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Erlotinib can cause excessive eyelash growth.

Dutasteride may help treat frontal fibrosing alopecia.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

An arthritis drug helped a person with severe hair loss regrow their hair.

Blocking YAP/TAZ could be a new way to treat skin cancer.

Some dibenzo compounds might help treat cancer with fewer side effects.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Ritlecitinib is an effective new treatment for Alopecia Areata.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Taxane chemotherapy can cause skin, hair, and nail side effects, which are often under-reported and can affect patient quality of life.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.

Analog 23 is a promising compound for prostate cancer treatment.

Ritlecitinib can help about 14,000 people with severe hair loss.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.